Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-736-8 | CAS number: 149-30-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 8.8 mg/m³
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 70.4 mg/m³
DNEL related information
Local effects
Acute/short term exposure
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 5 mg/kg bw/day
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 40 mg/kg bw/day
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- sensitisation (skin)
Acute/short term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- sensitisation (skin)
Workers - Hazard for the eyes
Additional information - workers
Acute/short-term local effects/ Long-term exposure local effects
The test substance is not skin and eye irritating.
Data from animal studies and data from human volunteers as well as data from epidemiological studies demonstrated a skin sensitizing potential of MBT (for review SCCP 2005, BG Chemie 2000). In consequence, an existing classification with R43 (22 ATP)/ GHS Skin Sensitizer category 1 is confirmed. According to criteria published in REACH guidance document chapter R.8, MBT was categorised as moderate skin sensitizer.
Acute/short-term exposure systemic effects:
The acute dermal and oral toxicity of the test substance MBT is very low, indicated by oral LD50 values greater than 2000 mg/kg. The acute oral LD50 value in rats is >= 2830 mg/kg bw (Monsanto Co. 1973, 1974) and the dermal LD50 value in rabbits is greater than 7940 mg/kg bw (Monsanto Co. 1973, 1974). Due to the very low oral and dermal acute toxicity of MBT it is proposed to limit exposure peaks to a factor of 8. This approach is generally in line with the regulatory procedure in Germany (see Technical Rule for Hazardous Substances 900).
DNEL short-term systemic dermal: 5 mg/kg bw/day x 8 = 40 mg/kg bw/day
DNEL short-term systemic inhalation: 8.8 mg/m3 x 8 = 70.4 mg/m3
DNEL long-term exposure systemic
The data discussed under repeated dose toxicity were used in a weight of evidence to assess a NOAEL in rats (for more details see chapter 5.6.). Mild toxic effects, like body weight reduction and/or increase in kidney and liver weights were noted in a concentration range of 150 to 375 mg/kg bw and day in rats. Following the recommendation given in MAK (1999) a NOAEL of 50 mg/kg bw and day was suggested, which based on data from the two-generation toxicity study and the observed LOAEL of 2500 ppm (ca. 150 to 250 mg/kg bw and day)(CMA 1990).
Worker DNEL long-term systemic for oral route
Start point: NOAEL 50 mg/mg bw and day 2-generation study with Sprague-Dawley rats (CMA 1990 according to MAK 1999).
Differences in absorption Abs (oral-rat) / Abs (oral-human): 1
=> Corrected NOAEL 50 mg/kg bw/day
Interspecies differences: Allometric scaling: 4
Remaining interspecies differences: 1*
Intraspecies differences: 5
Differences in duration of exposure (2-generation study to chronic): 1**
Dose response and endpoint specific/severity issues: 1
Quality of database: 1
Overall factor (product of individual factors): 20
=>Worker DNEL long-term for oral route-systemic: 2.5 mg/kg bw/day
* Repeated dose toxicity data from different rat and mice strains available
** In several repeated dose studies the NOAEL and or LOAEL are in the same range; consistent findings in subchronic, chronic and reproduction/ developmental toxicity study
Worker DNEL long-term sytemic for dermal route
Start point: NOAEL 50 mg/mg bw and day 2-generation study with Sprague-Dawley rats (CMA 1990 according to MAK 1999).
Differences in absorption Abs (oral-rat) / Abs (dermal-human): 2*
=> Corrected NOAEL 100 mg/kg bw/day
Interspecies differences: Allometric scaling: 4
Remaining interspecies differences: 1**
Intraspecies differences: 5
Differences in duration of exposure (2-generation study to chronic): 1***
Dose response and endpoint specific/severity issues: 1
Quality of database: 1
Overall factor (product of individual factors): 20
=>Worker DNEL long-term for dermal route-systemic: 5 mg/kg bw/day
* Toxicokinetic data revealed low dermal absorption
** Repeated dose toxicity data from different rat and mice strains available
*** In several repeated dose studies the NOAEL and or LOAEL are in the same range; consistent findings in subchronic, chronic and reproduction/ developmental toxicity study
Worker DNEL long-term systemic for inhalation route
Start point: NOAEL 50 mg/mg bw and day 2-generation study with Sprague-Dawley rats (CMA 1990 according to MAK 1999).
Respiratory volume rat (sRV) (worker (8 h): 1/0.38): 2.632
Differences in respiratory volume (default factor "light activity worker"): 0.67
Differences in absorption Abs (oral-rat) / Abs (inhalation-human): 1
=>Corrected NOAEC: 88.2 mg/m3
Interspecies differences: Allometric scaling: 1
Remaining interspecies differences: 1*
Intraspecies differences: 5
Differences in duration of exposure (2-generation study to chronic): 1**
Dose response and endpoint specific/severity issues: 1
Quality of database: 2***
Overall factor (product of individual factors): 10
=>Worker DNEL long-term for inhalation route-systemic: 8.8 mg/m3
* Repeated dose toxicity data from different rat and mice strains available
** In several repeated dose studies the NOAEL and or LOAEL are in the same range; consistent findings in subchronic, chronic and reproduction/ developmental toxicity study
* ** Repeated dose toxicity inhalation study: no valid data available
DNEL fertility:
A two-generation reproduction toxicity study (CMA 1990) was performed to evaluate the potential of MBT on reproduction toxicity. No adverse effects on reproductive functions of the F0 or F1 generation were indicated up to highest dose evaluated (15000 ppm, ca 778 to 2633 mg/kg bw/d F0 and F1 males, ca. 745 to 1770 mg/kg bw/d F0 and F1 females). Minimal to mild toxic effects occurred in all treated groups in both F0 and F1 parental animals. Based on the reduction of body weight noted in F0 males and F1 males and females at the lowest dose group a LOAEL of 2500 ppm (ca. 150 to 250 mg/kg bw and day) was suggested. These data were used in a weight of evidence approach for systemic DNEL calculation (as discussed above). No additional DNEL fertility was calculated because the systemic DNEL covers the maternal toxic effects.
DNEL developmental toxicity:
The developmental toxicity of MBT was evaluated in a teratology study with New Zealand White rabbits (CMA 1989). The oral administration of MBT up to the highest dose group evaluated (300 mg/kg bw and day) during major organogenesis did not induce any developmental toxicity or teratogenicity. Maternal toxicity was evident only at 300 mg/kg bw and day as slightly decreased body weight gain and slightly elevated liver weight. Based on these findings a NOAEL maternal/foetal of 300 mg/kg bw and day was suggested. Both NOAELs are above the suggested NOAEL systemic (50 mg/kg bw/and day) and thus it was concluded that the DNEL for long-term exposure covers the DNEL developmental toxicity.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.2 mg/m³
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 17.6 mg/m³
DNEL related information
Local effects
Acute/short term exposure
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.5 mg/kg bw/day
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 20 mg/kg bw/day
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- sensitisation (skin)
Acute/short term exposure
- Hazard assessment conclusion:
- no-threshold effect and/or no dose-response information available
- Most sensitive endpoint:
- sensitisation (skin)
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.25 mg/kg bw/day
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 10 mg/kg bw/day
DNEL related information
General Population - Hazard for the eyes
Additional information - General Population
Acute/short-term local effects/ Long-term exposure local effects
The test substance is not skin and eye irritating.
Data from animal studies and data from human volunteers as well as data from epidemiological studies demonstrated a skin sensitizing potential of MBT (for review SCCP 2005, BG Chemie 2000). In consequence, an existing classification with R43 (22 ATP)/ GHS Skin Sensitizer category 1 is confirmed. According to criteria published in REACH guidance document chapter R.8, MBT was categorised as moderate skin sensitizer.
Acute/short-term exposure systemic effects:
The acute dermal and oral toxicity of the test substance MBT is very low, indicated by oral LD50 values greater than 2000 mg/kg. The acute oral LD50 value in rats is >= 2830 mg/kg bw (Monsanto Co. 1973, 1974) and the dermal LD50 value in rabbits is greater than 7940 mg/kg bw (Monsanto Co. 1973, 1974). Due to the very low oral and dermal acute toxicity of DCBS it is proposed to limit exposure peaks to a factor of 8. This approach is generally in line with the regulatory procedure in Germany (see Technical Rule for Hazardous Substances 900).
DNEL short-term systemic oral: 1.25 mg/kg bw/day x 8 = 10 mg/kg bw/day
DNEL short-term systemic dermal: 2.5 mg/kg bw/day x 8 = 20 mg/kg bw/day
DNEL short-term systemic inhalation: 2.2 mg/m3 x 8 = 17.6 mg/m3
General public long-term exposure systemic
General public long-term systemic for oral route
Start point: NOAEL 50 mg/mg bw and day 2-generation study with Sprague-Dawley rats (CMA 1990 according to MAK 1999).
Differences in absorption Abs (oral-rat) / Abs (oral-human): 1
=> Corrected NOAEL 50 mg/kg bw/day
Interspecies differences: Allometric scaling: 4
Remaining interspecies differences: 1*
Intraspecies differences: 10
Differences in duration of exposure (2-generation study to chronic): 1**
Dose response and endpoint specific/severity issues: 1
Quality of database: 1
Overall factor (product of individual factors): 40
=> General Public long-term for oral route-systemic: 1.25 mg/kg bw/day
* Repeated dose toxicity data from different rat and mice strains available
** In several repeated dose studies the NOAEL and or LOAEL are in the same range; consistent findings in subchronic, chronic and reproduction/ developmental toxicity study
General public long-term systemic for dermal route
Start point: NOAEL 50 mg/mg bw and day 2-generation study with Sprague-Dawley rats (CMA 1990 according to MAK 1999).
Differences in absorption Abs (oral-rat) / Abs (dermal-human): 2*
=> Corrected NOAEL 100 mg/kg bw/day
Interspecies differences: Allometric scaling: 4
Remaining interspecies differences: 1**
Intraspecies differences: 10
Differences in duration of exposure (2-generation study to chronic): 1***
Dose response and endpoint specific/severity issues: 1
Quality of database: 1
Overall factor (product of individual factors): 40
=>General public long-term for dermal route-systemic: 2.5 mg/kg bw/day
* Toxicokinetic data revealed low dermal absorption
** Repeated dose toxicity data from different rat and mice strains available
*** In several repeated dose studies the NOAEL and or LOAEL are in the same range; consistent findings in subchronic, chronic and reproduction/ developmental toxicity study
General public long-term systemic for inhalation route
Start point: NOAEL 50 mg/mg bw and day 2-generation study with Sprague-Dawley rats (CMA 1990 according to MAK 1999).
Respiratory volume rat (sRV) general public 1/1.15: 0.87
Differences in absorption Abs (oral-rat) / Abs (inhalation-human): 1
=> Corrected NOAEC: 43.5 mg/m3
Interspecies differences: Allometric scaling: 1
Remaining interspecies differences: 1*
Intraspecies differences: 10
Differences in duration of exposure (2-generation study to chronic): 1**
Dose response and endpoint specific/severity issues: 1
Quality of database: 2***
Overall factor (product of individual factors): 20
=>General Public DNEL long-term for inhalation route-systemic: 2.2 mg/m3
* Repeated dose toxicity data from different rat and mice strains available
** In several repeated dose studies the NOAEL and or LOAEL are in the same range; consistent findings in subchronic, chronic and reproduction/ developmental toxicity study
* ** Repeated dose toxicity inhalation study: no valid data available
DNEL fertility:
A two-generation reproduction toxicity study (CMA 1990) was performed to evaluate the potential of MBT on reproduction toxicity. No adverse effects on reproductive functions of the F0 or F1 generation were indicated up to highest dose evaluated (15000 ppm, ca 778 to 2633 mg/kg bw/d F0 and F1 males, ca. 745 to 1770 mg/kg bw/d F0 and F1 females). Minimal to mild toxic effects occurred in all treated groups in both F0 and F1 parental animals. Based on the reduction of body weight noted in F0 males and F1 males and females at the lowest dose group a LOAEL of 2500 ppm (ca. 150 to 250 mg/kg bw and day) was suggested. These data were used in a weight of evidence approach for systemic DNEL calculation (as discussed above). No additional DNEL fertility was calculated because the systemic DNEL covers the maternal toxic effects.
DNEL developmental toxicity:
The developmental toxicity of MBT was evaluated in a teratology study with New Zealand White rabbits (CMA 1989). The oral administration of MBT up to the highest dose group evaluated (300 mg/kg bw and day) during major organogenesis did not induce any developmental toxicity or teratogenicity. Maternal toxicity was evident only at 300 mg/kg bw and day as slightly decreased body weight gain and slightly elevated liver weight. Based on these findings a NOAEL maternal/foetal of 300 mg/kg bw and day was suggested. Both NOAELs are above the suggested NOAEL systemic (50 mg/kg bw/and day) and thus it was concluded that the DNEL for long-term exposure covers the DNEL developmental toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.